Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Liver Transplantation

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 102 articles:
HTML format



Single Articles


    December 2025
  1. LI H, Zhao R, Zheng S, Xu X, et al
    Recurrence pattern for HBV-related HCC after liver transplantation in the antiviral era.
    J Hepatol. 2025 Dec 10:S0168-8278(25)02716-3. doi: 10.1016/j.jhep.2025.
    PubMed    


    October 2025
  2. LAMARQUE C, Segaux L, Bachellier P, Buchard B, et al
    Corrigendum to: "Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study" [J Hepatol (2024) 278-288].
    J Hepatol. 2025 Oct 27:S0168-8278(25)02553-X. doi: 10.1016/j.jhep.2025.
    PubMed    


  3. WEDEMEYER H, Tacke F, Newsome P, Ratziu V, et al
    The first human xenogeneic liver transplantation - A landmark event, but what does it mean for hepatology?
    J Hepatol. 2025 Oct 9:S0168-8278(25)02496-1. doi: 10.1016/j.jhep.2025.
    PubMed    


  4. YANG P, Wang X, Wu W, Yuan J, et al
    Decoding the resistin-CAP1 pathway in intermediate monocytes mediating liver allograft rejection.
    J Hepatol. 2025;83:931-945.
    PubMed     Abstract available


  5. RUSSO FP, Murad SD, Pillai AA, Shingina A, et al
    Combined liver with other solid organ transplants: Promises, pitfalls and ethical dilemmas.
    J Hepatol. 2025;83:982-988.
    PubMed     Abstract available


    September 2025
  6. WEHRLE CJ, Fujiki M, Uso TD, Hashimoto K, et al
    Portal Venous Flow in Pediatric Liver Transplantation.
    J Hepatol. 2025 Sep 2:S0168-8278(25)02467-5. doi: 10.1016/j.jhep.2025.
    PubMed    


    August 2025
  7. VAZ J, Hagstrom H
    Phosphatidylethanol for monitoring alcohol use after liver transplantation.
    J Hepatol. 2025 Aug 30:S0168-8278(25)02461-4. doi: 10.1016/j.jhep.2025.
    PubMed    


  8. ROSSIGNOL G, Muller X, Dubois R, Mohkam K, et al
    Hemodynamic Graft-Recipient Matching in Pediatric Liver Transplantation: Just Graft with the Flow.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02448-1. doi: 10.1016/j.jhep.2025.
    PubMed    


    July 2025
  9. ENGEL B, Alaswad A, Campos-Murguia A, Zoodsma M, et al
    Molecular signatures discriminating different types of rejection in human liver transplants.
    J Hepatol. 2025 Jul 14:S0168-8278(25)02338-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available


  10. WEHRLE CJ, Fujiki M, Satish S, Iuppa G, et al
    Mechanisms and Management of Graft In- and Out-flow in Liver Transplantation: A Narrative Review of the Literature and Guide for Interventional Management.
    J Hepatol. 2025 Jul 4:S0168-8278(25)02324-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available


    June 2025
  11. HESSHEIMER AJ, Hartog H, Marcon F, Schlegel A, et al
    Deceased donor liver utilisation and assessment: Consensus guidelines from the European Liver and Intestine Transplant Association.
    J Hepatol. 2025;82:1089-1109.
    PubMed     Abstract available


    May 2025
  12. GANGADHAR A, Hasjim BJ, Zhao X, Sun Y, et al
    Personalized survival benefit estimation from living donor liver transplantation with a novel machine learning method for confounding adjustment.
    J Hepatol. 2025 May 28:S0168-8278(25)02253-6. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available



  13. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis.
    J Hepatol. 2025 May 10:S0168-8278(25)00173-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available


    April 2025
  14. MOORE LW, Brombosz EW, Ghobrial RM
    To Sleeve or Not to Sleeve: Validation of Liver Transplantation with Sleeve Gastrectomy.
    J Hepatol. 2025 Apr 15:S0168-8278(25)00242-9. doi: 10.1016/j.jhep.2025.
    PubMed    


  15. BURKE L, Bernal W, Pirani T, Agarwal B, et al
    Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohort.
    J Hepatol. 2025;82:615-621.
    PubMed     Abstract available


    March 2025
  16. HUWYLER F, Pfister M, Binz J, Tibbitt MW, et al
    Benefits of multi-day ex situ perfusion include dampened ischemia reperfusion injury in liver transplantation.
    J Hepatol. 2025 Mar 25:S0168-8278(25)00208-9. doi: 10.1016/j.jhep.2025.
    PubMed    


  17. LARSON EL, Ellias SD, Blezek DJ, Klug J, et al
    Simultaneous liver transplant and sleeve gastrectomy provides durable weight loss, improves metabolic syndrome and reduces allograft steatosis.
    J Hepatol. 2025 Mar 13:S0168-8278(25)00139-4. doi: 10.1016/j.jhep.2025.
    PubMed     Abstract available


  18. ARTRU F, Ursic-Bedoya J, L'Hermite S, Saliba F, et al
    Reply to : "Long-term outcome following liver transplantation of patients with ACLF grade 3 : Need of redefining boundaries ?".
    J Hepatol. 2025 Mar 5:S0168-8278(25)00133-3. doi: 10.1016/j.jhep.2025.
    PubMed    


  19. EDEN J, Thorne AM, Bodewes SB, Patrono D, et al
    Assessment of liver graft quality during hypothermic oxygenated perfusion: The first international validation study.
    J Hepatol. 2025;82:523-534.
    PubMed     Abstract available


    February 2025
  20. HE K, Chen L, Xia Q
    Is MELD-Cr an Accurate Predictor of Liver Transplant Outcomes? A Call for Refinement in Allocation Criteria.
    J Hepatol. 2025 Feb 20:S0168-8278(25)00095-9. doi: 10.1016/j.jhep.2025.
    PubMed    


  21. ROSENSTENGLE C, Serper M, Asrani SK, Bittermann T, et al
    Variation in intention-to-treat survival by MELD subtypes: All models created for end-stage liver disease are not equal.
    J Hepatol. 2025;82:268-276.
    PubMed     Abstract available


    January 2025
  22. MISHRA AK
    Long-term outcome following liver transplantation of patients with ACLF grade 3 : Need of redefining boundaries?
    J Hepatol. 2025 Jan 23:S0168-8278(25)00024-8. doi: 10.1016/j.jhep.2025.
    PubMed    


  23. ACEITUNO L, Gravely AK, O'Kane GM, Vogel A, et al
    The use of immunotherapy pre-liver transplant.
    J Hepatol. 2025 Jan 3:S0168-8278(24)02702-8. doi: 10.1016/j.jhep.2024.
    PubMed    


  24. REZAEE-ZAVAREH MS, Yeo YH, Wang T, Guo Z, et al
    Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.
    J Hepatol. 2025;82:107-119.
    PubMed     Abstract available


  25. EDEN J, Bruggenwirth IMA, Berlakovich G, Buchholz BM, et al
    Long-term outcomes after hypothermic oxygenated machine perfusion and transplantation of 1,202 donor livers in a real-world setting (HOPE-REAL study).
    J Hepatol. 2025;82:97-106.
    PubMed     Abstract available


    December 2024

  26. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.
    J Hepatol. 2024 Dec 16:S0168-8278(24)02508-X. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


    November 2024
  27. DE GOEIJ FHC, Wehrle CJ, Abassi F, Satish S, et al
    Mastering the Narrative: Precision Reporting of Risk and Outcomes in Liver Transplantation.
    J Hepatol. 2024 Nov 16:S0168-8278(24)02713-2. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


    October 2024
  28. SAMUEL D
    EASL Clinical Practice Guidelines on liver transplantation.
    J Hepatol. 2024 Oct 23:S0168-8278(24)02440-1. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


  29. PARENTE A, Wehrle CJ, Schold JD, Panconesi R, et al
    Reply to: "Trends in current use of machine perfusion for donation after cardiac death donors in the US".
    J Hepatol. 2024;81:e189-e191.
    PubMed    


  30. MATEVISH LE, Vagefi PA, Patel MS
    Trends in current use of machine perfusion for donation after cardiac death donors in the US.
    J Hepatol. 2024;81:e187-e188.
    PubMed    


    September 2024
  31. REZAEE-ZAVAREH MS, Guo Z, Yang JD
    Addressing the Complexities of Pre-Liver Transplant Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Response to Recent Commentaries.
    J Hepatol. 2024 Sep 19:S0168-8278(24)02558-3. doi: 10.1016/j.jhep.2024.
    PubMed    


  32. TABRIZIAN P, Holzner M, Ajmera V, Kim AK, et al
    Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study.
    J Hepatol. 2024 Sep 8:S0168-8278(24)02541-8. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


  33. ALLEN E, Taylor R, Gimson A, Thorburn D, et al
    Transplant benefit-based offering of deceased donor livers in the United Kingdom.
    J Hepatol. 2024;81:471-478.
    PubMed     Abstract available


    August 2024
  34. MAGAZ M, Giudicelli-Lett H, G Abraldes J, Nicoara-Farcau O, et al
    Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome.
    J Hepatol. 2024 Aug 22:S0168-8278(24)02481-4. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


  35. DE HAAN J, Termorshuizen F, de Keizer N, Gommers D, et al
    One-year transplant-free survival following hospital discharge after ICU admission for ACLF in the Netherlands.
    J Hepatol. 2024;81:238-247.
    PubMed     Abstract available


    July 2024
  36. VAN LEEUWEN LL, Irizar H, Kim-Schluger L, Florman S, et al
    The Potential of Machine Learning to Predict Early Allograft Dysfunction after Normothermic Machine Perfusion in Liver transplantation.
    J Hepatol. 2024 Jul 31:S0168-8278(24)02438-3. doi: 10.1016/j.jhep.2024.
    PubMed    


  37. HAO L, Shan D, Xue J
    Strategic Timing and Patient Selection for ICIs Prior to Liver Transplantation for HCC.
    J Hepatol. 2024 Jul 27:S0168-8278(24)02432-2. doi: 10.1016/j.jhep.2024.
    PubMed    


  38. ARTRU F, Sacleux SC, Ursic-Bedoya J, Ntandja Wandji LC, et al
    Long-term outcome following liver transplantation of patients with ACLF grade 3.
    J Hepatol. 2024 Jul 7:S0168-8278(24)02346-8. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


    June 2024
  39. FUSTER-ANGLADA C, Mauro E, Ferrer-Fabrega J, Caballol B, et al
    Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection.
    J Hepatol. 2024 Jun 24:S0168-8278(24)02324-9. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


  40. ESSER H, Kilpatrick AM, Man TY, Aird R, et al
    Primary cilia as a targetable node between biliary injury, senescence and regeneration in liver transplantation.
    J Hepatol. 2024 Jun 13:S0168-8278(24)02302-X. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


  41. HE T, Sun K, Zou J
    Biomarker predictors and LRT strategies for HCC recurrence post-liver transplantation: A comment.
    J Hepatol. 2024 Jun 6:S0168-8278(24)00422-7. doi: 10.1016/j.jhep.2024.
    PubMed    


  42. LI M, Bhoori S, Mehta N, Mazzaferro V, et al
    Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.
    J Hepatol. 2024 Jun 5:S0168-8278(24)00423-9. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


  43. NORMAN JS, Mehta N
    Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
    J Hepatol. 2024;80:e273-e274.
    PubMed    


    May 2024
  44. CHICHELNITSKIY E, Goldschmidt I, Ruhl L, Rubsamen N, et al
    Plasma immune signatures can predict rejection-free survival in the first year after pediatric liver transplantation.
    J Hepatol. 2024 May 29:S0168-8278(24)00367-2. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


  45. MONTANO-LOZA AJ, Lytvyak E, Hirschfield G, Hansen BE, et al
    Prognostic Scores for Ursodeoxycholic Acid-Treated Patients Predict Graft Loss and Mortality in Recurrent Primary Biliary Cholangitis after Liver Transplantation.
    J Hepatol. 2024 May 29:S0168-8278(24)00345-3. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


  46. SPADA M, Angelico R, Trapani S, Masiero L, et al
    Reply to: "Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding".
    J Hepatol. 2024 May 15:S0168-8278(24)00346-5. doi: 10.1016/j.jhep.2024.
    PubMed    


  47. GAMBELLA A, Salvi M, Molinari F
    Response to: Application of Digital Pathology in Liver Transplantation.
    J Hepatol. 2024 May 15:S0168-8278(24)00350-7. doi: 10.1016/j.jhep.2024.
    PubMed    


  48. MULLER X, Rossignol G, Boulanger N, Mohkam K, et al
    In situ or ex situ split: Does it all come down to static cold storage?
    J Hepatol. 2024;80:e210-e211.
    PubMed    


    March 2024
  49. LI Y, Yang F, Liu K
    Application of Digital Pathology in Liver Transplantation.
    J Hepatol. 2024 Mar 23:S0168-8278(24)00207-1. doi: 10.1016/j.jhep.2024.
    PubMed    


  50. LAMARQUE C, Segaux L, Bachellier P, Buchard B, et al
    Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study.
    J Hepatol. 2024 Mar 21:S0168-8278(24)00202-2. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


  51. GAMBELLA A, Salvi M, Molinaro L, Patrono D, et al
    Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms.
    J Hepatol. 2024;80:495-504.
    PubMed     Abstract available


    February 2024
  52. MARTIN-MATEOS R, Martinez-Arenas L, Carvalho-Gomes A, Aceituno L, et al
    Multidrug-resistant bacterial infections after liver transplantation: prevalence, impact, and risk factors.
    J Hepatol. 2024 Feb 28:S0168-8278(24)00128-4. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available


  53. DE VILLE DE GOYET J
    Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding: Comment on:Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period. Spada M,
    J Hepatol. 2024 Feb 12:S0168-8278(24)00126-0. doi: 10.1016/j.jhep.2024.
    PubMed    


  54. SOIN A, Lesurtel M, Clavien PA
    To the editor: Reply to the letter by Liu et al. entitled "Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis".
    J Hepatol. 2024 Feb 8:S0168-8278(24)00101-6. doi: 10.1016/j.jhep.2024.
    PubMed    


    January 2024
  55. LAUTERIO A, Cillo U, De Carlis R, Bernasconi D, et al
    Reply to: "Outcome of in-situ split liver transplantation in Italy over the last 25 years: an alternative analysis and personal view".
    J Hepatol. 2024 Jan 25:S0168-8278(24)00057-6. doi: 10.1016/j.jhep.2024.
    PubMed    


  56. TABRIZIAN P, Abdelrahim M, Schwartz M
    Immunotherapy and Transplantation for Hepatocellular Carcinoma.
    J Hepatol. 2024 Jan 20:S0168-8278(24)00053-9. doi: 10.1016/j.jhep.2024.
    PubMed    


    December 2023
  57. NORMAN JS, Mehta N
    Reply to: Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Dec 26:S0168-8278(23)05371-0. doi: 10.1016/j.jhep.2023.
    PubMed    


  58. SPADA M, Angelico R, Trapani S, Masiero L, et al
    Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period.
    J Hepatol. 2023 Dec 18:S0168-8278(23)05308-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  59. SMEETS JJH, van Malenstein H, van der Merwe S, Nevens F, et al
    SARS-CoV-2 anti-spike IgG antibodies are present in all liver transplant recipients after fifth vaccine dose.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05362-X. doi: 10.1016/j.jhep.2023.
    PubMed    


  60. PARENTE A, Jiao C, Eden J, Dutkowski P, et al
    machine perfusion, randomized controlled trials, liver transplantation, immune cellsPerfusate immune cell profiling during machine perfusion - A new tool to link risk and immune response after liver transplantation?
    J Hepatol. 2023 Dec 16:S0168-8278(23)05364-3. doi: 10.1016/j.jhep.2023.
    PubMed    


  61. HAHN M, Herber A, Berg T, Seehofer D, et al
    Enhancing HCC Recurrence Prediction after Liver Transplantation: from DCP plus AFP-L3 model to GALAD Score.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05357-6. doi: 10.1016/j.jhep.2023.
    PubMed    


  62. DE CARLIS R, Lauterio A, Bernasconi D, Taner B, et al
    Reply to: "Excellent long-term outcomes after sequential hypothermic and normothermic machine perfusion challenges the importance of functional donor warm ischemia time in DCD liver transplantation": Further comments on the changing role of donor warm
    J Hepatol. 2023;79:e245-e247.
    PubMed    


    November 2023
  63. PARENTE A, Dondossola D, Dutkowski P, Schlegel A, et al
    Current evidence on the beneficial HOPE-effect based on systematic reviews and meta-analyses in liver transplantation.
    J Hepatol. 2023 Nov 10:S0168-8278(23)05233-9. doi: 10.1016/j.jhep.2023.
    PubMed    


  64. LIU J, Qian J, Yang Z, Zhou L, et al
    Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation:A meta-analysis.
    J Hepatol. 2023 Nov 6:S0168-8278(23)05231-5. doi: 10.1016/j.jhep.2023.
    PubMed    


    October 2023
  65. MURRAY SM, Pose E, Wittner M, Londono MC, et al
    Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and in liver transplant recipients.
    J Hepatol. 2023 Oct 18:S0168-8278(23)05174-7. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  66. DE VILLE DE GOYET J
    Outcome of in-situ split liver transplantation in Italy over the last 25 years : an alternative analysis and personal view.
    J Hepatol. 2023 Oct 12:S0168-8278(23)05151-6. doi: 10.1016/j.jhep.2023.
    PubMed    


  67. SHA M, Cao J, Xia Q
    Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Oct 9:S0168-8278(23)05162-0. doi: 10.1016/j.jhep.2023.
    PubMed    


    September 2023
  68. ABERG F, Sallinen V, Tuominen S, Adam R, et al
    Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity-score matched intention-to-treat analysis.
    J Hepatol. 2023 Sep 16:S0168-8278(23)05100-0. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  69. CHOUDHARY NS, Dhampalwar S, Saraf N, Soin AS, et al
    Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
    J Hepatol. 2023 Sep 15:S0168-8278(23)05098-5. doi: 10.1016/j.jhep.2023.
    PubMed    


  70. NORMAN JS, Li PJ, Kotwani P, Shui AM, et al
    AFP-L3 and DCP Strongly Predict Early Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    J Hepatol. 2023 Sep 6:S0168-8278(23)05074-2. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  71. HERNAEZ R, Karvellas CJ, Liu Y, Sacleux SC, et al
    The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure.
    J Hepatol. 2023;79:717-727.
    PubMed     Abstract available


  72. EDEN J, Dutkowski P, Schlegel A
    Reply to: "How many liver grafts could be recovered after implementation of donation after cardiac death in Germany?".
    J Hepatol. 2023;79:e120-e121.
    PubMed    


  73. EDEN J, von Felten S, Dutkowski P, Schlegel A, et al
    Reply to: "A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation".
    J Hepatol. 2023;79:e116-e118.
    PubMed    


  74. SHARMA N, Pandey S, Yadav M, Mathew B, et al
    Biomolecular map of albumin identifies signatures of severity and early mortality in acute liver failure.
    J Hepatol. 2023;79:677-691.
    PubMed     Abstract available


  75. HAKEEM AR, Taylor R, Prasad R
    Comment on "Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicentre analysis of the US, the UK, and Canada".
    J Hepatol. 2023;79:e112-e114.
    PubMed    


  76. CZIGANY Z, Michalski CW
    A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation.
    J Hepatol. 2023;79:e114-e116.
    PubMed    


    August 2023
  77. TANG G, Zhang L, Zhou R
    Letter to the Editor: Machine perfusion techniques for liver transplantation - A meta-analysis of the first seven randomized controlled trials.
    J Hepatol. 2023 Aug 8:S0168-8278(23)05045-6. doi: 10.1016/j.jhep.2023.
    PubMed    



  78. EASL Clinical Practice Guidelines on acute-on-chronic liver failure.
    J Hepatol. 2023;79:461-491.
    PubMed     Abstract available


  79. KARTOUN U
    Fairness metrics: Additional principles to consider for improving MELD.
    J Hepatol. 2023;79:e80-e81.
    PubMed    


    July 2023
  80. VAN LEEUWEN OB, Bodewes SB, Porte RJ, de Meijer VE, et al
    Excellent long-term outcome after sequential hypothermic and normothermic machine perfusion challenges the importance of functional donor warm ischemia time in DCD liver transplantation.
    J Hepatol. 2023 Jul 27:S0168-8278(23)05004-3. doi: 10.1016/j.jhep.2023.
    PubMed    


  81. LAUTERIO A, Cillo U, Spada M, Trapani S, et al
    Improving outcomes of in situ split liver transplantation in Italy over the last 25 years.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04988-7. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


    June 2023
  82. BRAADLAND PR, Bergquist A, Kummen M, Bossen L, et al
    Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation.
    J Hepatol. 2023 Jun 14:S0168-8278(23)00415-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  83. LIM WH, Ng CH, Hao Tan DJ, Tseng M, et al
    Natural history of NASH cirrhosis in liver transplant waitlist registrants.
    J Hepatol. 2023 Jun 10:S0168-8278(23)00412-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  84. PARENTE A, Tirotta F, Pini A, Eden J, et al
    Machine perfusion techniques for liver transplantation - A meta-analysis of the first seven randomized controlled trials.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00399-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  85. KAPLAN A, Korenjak M, Brown RS Jr
    Post-liver transplantation patient experience.
    J Hepatol. 2023;78:1234-1244.
    PubMed     Abstract available


  86. BHAT M, Rabindranath M, Chara BS, Simonetto DA, et al
    Artificial intelligence, machine learning, and deep learning in liver transplantation.
    J Hepatol. 2023;78:1216-1233.
    PubMed     Abstract available


  87. MONTANO-LOZA AJ, Rodriguez-Peralvarez ML, Pageaux GP, Sanchez-Fueyo A, et al
    Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation.
    J Hepatol. 2023;78:1199-1215.
    PubMed     Abstract available


  88. DE CARLIS R, Paolo Muiesan, Taner B
    Donation after circulatory death: Novel strategies to improve the liver transplant outcome.
    J Hepatol. 2023;78:1169-1180.
    PubMed     Abstract available


  89. GERMANI G, Mathurin P, Lucey MR, Trotter J, et al
    Early liver transplantation for severe acute alcohol-related hepatitis after more than a decade of experience.
    J Hepatol. 2023;78:1130-1136.
    PubMed     Abstract available


  90. SOIN A, Lesurtel M, Bhangui P, Cocchi L, et al
    Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?
    J Hepatol. 2023;78:1124-1129.
    PubMed     Abstract available


  91. ARTRU F, Goldberg D, Kamath PS
    Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation?
    J Hepatol. 2023;78:1118-1123.
    PubMed     Abstract available


  92. TANDON P, Zanetto A, Piano S, Heimbach JK, et al
    Liver transplantation in the patient with physical frailty.
    J Hepatol. 2023;78:1105-1117.
    PubMed     Abstract available


  93. BURRA P
    The changing world of liver transplantation.
    J Hepatol. 2023;78:1087-1088.
    PubMed    


  94. SCHLEGEL A, Mergental H, Fondevila C, Porte RJ, et al
    Machine perfusion of the liver and bioengineering.
    J Hepatol. 2023;78:1181-1198.
    PubMed     Abstract available


  95. TANER T, Hilscher MB, Broda CR, Drenth JPH, et al
    Issues in multi-organ transplantation of the liver with kidney or heart in polycystic liver-kidney disease or congenital heart disease: Current practices and immunological aspects.
    J Hepatol. 2023;78:1157-1168.
    PubMed     Abstract available


  96. KASAHARA M, Hong JC, Dhawan A
    Evaluation of living donors for hereditary liver disease (siblings, heterozygotes).
    J Hepatol. 2023;78:1147-1156.
    PubMed     Abstract available


    May 2023
  97. EDEN J, Sousa Da Silva R, Cortes-Cerisuelo M, Croome K, et al
    Utilization of livers donated after circulatory death for transplantation - An international comparison.
    J Hepatol. 2023;78:1007-1016.
    PubMed     Abstract available


    April 2023
  98. GUO Z, Zhao Q, Jia Z, Huang C, et al
    A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease.
    J Hepatol. 2023 Apr 20:S0168-8278(23)00233-7. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available


  99. SCHLEGEL A, Mueller M, Muller X, Eden J, et al
    A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation.
    J Hepatol. 2023;78:783-793.
    PubMed     Abstract available


    March 2023
  100. MOOSBURNER S, Sauer IM, Weiss B, Pratschke J, et al
    How many liver transplantations could be recovered after implementation of donation after cardiac death in Germany?
    J Hepatol. 2023 Mar 11:S0168-8278(23)00176-9. doi: 10.1016/j.jhep.2023.
    PubMed    


  101. GE J, Kim WR, Lai JC, Kwong AJ, et al
    Response to: "Towards optimally replacing the current version of MELD".
    J Hepatol. 2023;78:e100-e101.
    PubMed    


  102. KARTOUN U
    Towards optimally replacing the current version of MELD.
    J Hepatol. 2023;78:e98-e99.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Liver Transplantation is free of charge.